| | 179545-77-8 Basic information More.. |
| Product Name: | Tanomastat | | Synonyms: | TANOMASTAT;BAY12-9566,(S)-4Chloro-g-oxo-a-[(phenylthio)methyl][1,1biphenyl]-4-butanoicAcid;(S)-4'-Chloro-g-oxo-a-[(phenylthio)methyl][1,1'-biphenyl]-4-butanoic acid;(S)-4-[4-(4-Chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid;D03802;Tanomastat (usan/inn);(S)-4-(4'-Chloro-[1,1'-biphenyl]-4-yl)-4-oxo-2-((phenylthio)methyl)butanoic acid;[1,1'-Biphenyl]-4-butanoic acid, 4'-chloro-γ-oxo-α-[(phenylthio)methyl]-, (αS)- | | CAS: | 179545-77-8 | | MF: | C23H19ClO3S | | MW: | 410.91 | | EINECS: | | | Mol File: | 179545-77-8.mol |  |
Use
Tanomastat is an orally available, non-peptidic inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, and MMP-9 (Kis = 11, 143, and 301 nM, respectively). It is active in various animal models of tumor metastasis and has been used in a phase III clinical trial in pancreatic, SCLC, NSCLC, and ovarian cancer patients.
|
|
179545-77-8
Recommend Suppliers |
|